Newsletter - All News

Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research

Category
Continent
From
To
 
YolTech Gets FDA IND OK for YOLT-101 to Treat Fami...

YolTech Gets FDA IND OK for YOLT-101 to Treat Fami...

Category : Clinical Trial Update 6 June 2025

YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing thera...
FutureCeuticals: vitAlign® Boosts Cellular Health...

FutureCeuticals: vitAlign® Boosts Cellular Health...

Category : Clinical Trial Update 6 June 2025

A new study published in the International Journal of Molecular Sciences  shows that vitAlign&r...
Halia completes Phase 2a trial enrollment for MDS...

Halia completes Phase 2a trial enrollment for MDS...

Category : Clinical Trial Update 6 June 2025

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering the development of genetic...
Elgan Pharma, Chiesi dose first infants in ELGN-21...

Elgan Pharma, Chiesi dose first infants in ELGN-21...

Category : Clinical Trial Update 6 June 2025

Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A today announced the dosing of the first participatin...
FDA Grants Orphan Drug Status to Sanofi's Rilzabru...

FDA Grants Orphan Drug Status to Sanofi's Rilzabru...

Category : ODD/BTA/FTA Status 5 June 2025

The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a no...

Categories

Latest Newsletter Post

Subscribe to Our Newsletter!

Subscribe to get latest updates and information.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!